Gilead Sciences top products by revenue 2021-2023

Veuillez noter que la page demandée n’est pas disponible dans la langue par défaut sélectionnée. Vous utilisez notre plateforme dans une autre langue maintenant.

This statistic shows the top products of biopharmaceutical company Gilead Sciences from 2021 to 2023, based on revenue. Gilead Sciences Inc. is headquartered in California and is specialized in discovering, developing and commercializing therapeutics. In 2023, Gilead Sciences' COVID-19 treatment Veklury (remdesivir) generated some 2.2 billion U.S. dollars in revenue, a significant decrease compared to 5.6 billion in 2021.

Leading products of Gilead Sciences from 2021 to 2023 based on revenue (in million U.S. dollars)

Characteristic	2021	2022	2023
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

February 2024

More information

Region

Worldwide

Survey time period

2021 to 2023

Special properties

Supplementary notes

* Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”).

Open this statistic in...

Spanish

Citation formats